PRTA Q3 2022 Earnings — Prothena Corporation plc Revenue & Financial Results | Market Cap Arena

PRTAProthena Corporation plc

$549M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-98.9% YoY

Gross Profit

-$38M-2527.6% margin

Operating Income

-$50M-3317.9% margin

Net Income

-$46M-3016.7% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+15.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$554M

Total Liabilities

$150M

Stockholders' Equity

$405M

Cash & Equivalents

$496M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$139M	-98.9%
Gross Profit	-$38M	$121M	-131.6%
Operating Income	-$50M	$109M	-146.1%
Net Income	-$46M	$109M	-141.9%

Revenue Segments

US Rights and Global Rights

$85M79%

Collaboration Revenue, US Development Services

$21M20%

Collaboration

$2M1%